Fate Therapeutics Inc. (FATE) fundamentals score
Fate Therapeutics has pioneered a therapeutic approach that it generally refers to as cellular programming: it creates and engineer human induced pluripotent stem cells (iPSCs) to incorporate novel synthetic controls of cell function; after the engineering step that incorporates multiple functional elements into the iPSCs, it generates a clonal master iPSC line for use as a renewable source of starting material for the manufacture of cell therapies; through the manufacturing process, it directs…
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 4.8 out of 10, Weak long-term fundamentals
- Growth: 4.8/10
- Profitability: 3.3/10
- Financial health: 5.5/10
- Earnings quality: 8.0/10
- Valuation: 2.9/10
Scores are calculated from Fate Therapeutics Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10